December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Cell Therapy: New Genetically "Immortalized" Human RPE Cell Lines
Author Affiliations & Notes
  • A zerbib
    Neurotech SA Evry France
  • S Porte
    Neurotech SA Evry France
  • G Puel
    Neurotech SA Evry France
  • A David
    Neurotech SA Evry France
  • M Neuner-Jehle
    Neurotech SA Evry France
  • S Paisant
    Neurotech SA Evry France
  • F Martin
    Neurotech SA Evry France
  • A Degeorges
    Neurotech SA Evry France
  • J Greenwood
    University College Institute of Ophthalmology London United Kingdom
  • J Crouzet
    Neurotech SA Evry France
  • Footnotes
    Commercial Relationships    A. zerbib, Neurotech SA E; S. Porte, Neurotech SA E; G. Puel, Neurotech SA E; A. David, Neurotech SA E; M. Neuner-Jehle, Neurotech SA E; S. Paisant, Neurotech SA E; F. Martin, Neurotech SA E; A. Degeorges, Neurotech SA E; J. Greenwood, Neurotech SA F; J. Crouzet, Neurotech SA E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4629. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A zerbib, S Porte, G Puel, A David, M Neuner-Jehle, S Paisant, F Martin, A Degeorges, J Greenwood, J Crouzet; Cell Therapy: New Genetically "Immortalized" Human RPE Cell Lines . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4629.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Neurotech is developing cell-based therapies for the treatment of ophthalmic disorders with a special interest in retinal diseases. One approach consists in using immortalised human retinal pigment epithelium (RPE) cell lines for replacement therapies in humans. This approach could be used in AMD or in genetic diseases associated with RPE cell impairment. Methods: Primary RPE cells were isolated from a human donor eye and immortalised cell lines were obtained by stepwise transfection with two genes: first, the SV40 large T antigen gene, then the gene encoding the catalytic component of human telomerase (hTERT). Proliferative and phenotypic characteristics were analysed at different steps of the immortalisation process. Results: Expression of the SV40 large T antigen gene was necessary to bypass senescence, and the obtained cell line retained typical properties of primary RPE culturesa. However, for bypassing cell crisis and maintaining cell proliferation and morphology, transfection of the hTERT gene was necessary. Four populations were independently derived, they retain the large T expression and display telomerase activity. All of them exhibit a cobblestone-like morphology, express cytokeratin 8 and 18, and display a junctional distribution of ZO-1 as detected by immonufluorescence. Cell clones were isolated from these populations: they are contact inhibited, serum dependent and could proliferate 50 population doublings beyond the cell crisis undergone by the large T positive / HTERT negative parental cell line. Conclusion: Transfection with two immortalising genes (SV40 large T Antigen and hTERT) was necessary to immortalise this primary culture and maintain typical RPE properties. aKanuga et al. IOVS, in press.

Keywords: 567 retinal pigment epithelium • 419 gene transfer/gene therapy • 308 age-related macular degeneration 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.